ABT-925

Uses your system voice; voice and rate in settings.

Snapshot

≈ 4 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ABT-925, also known as A-437203 or as LU-201640, is a selective dopamine D 3 receptor antagonist which was under development for the treatment of schizophrenia but was never marketed. It is taken orally. The drug shows affinity for the dopamine D 3 receptor and to a much lesser extent for the dopamine D 2 receptor, with K i values of 0.97–3.2 nM and 75 nM, respectively, and with 45- to 120-fold selectivity for the dopamine D 3 receptor over the dopamine D 2 receptor.

It showed little activity in classical tests of antipsychotic-like activity in rodents, for instance inhibition of methamphetamine-induced hyperlocomotion and inhibition of apomorphine-induced climbing behavior. The drug does not produce catalepsy and does not affect prolactin levels in rodents. The occupancy of the dopamine D 3 receptor by ABT-925 has been studied in humans. ABT-925 was first described in the scientific literature by 1997. At the time, it was the most potent and selective dopamine D 3 receptor antagonist yet known.

In addition, the drug has been said to have been the first selective dopamine D 3 receptor antagonist. It was under development by Abbott Laboratories. The drug reached phase 2 clinical trials prior to the discontinuation of its development. ABT-925 is known to have been in active phase 2 trials between 2001 and 2007.…

ABT-925, also known as A-437203 or as LU-201640, is a selective dopamine D 3 receptor antagonist which was under development for the treatment of schizophrenia but was never marketed. It is taken orally. The drug shows affinity for the dopamine D 3 receptor and to a much lesser extent for the dopamine D 2 receptor, with K i values of 0.97–3.2 nM and 75 nM, respectively, and with 45- to 120-fold selectivity for the dopamine D 3 receptor over the dopamine D 2 receptor.

It showed little activity in classical tests of antipsychotic-like activity in rodents, for instance inhibition of methamphetamine-induced hyperlocomotion and inhibition of apomorphine-induced climbing behavior. The drug does not produce catalepsy and does not affect prolactin levels in rodents. The occupancy of the dopamine D 3 receptor by ABT-925 has been studied in humans. ABT-925 was first described in the scientific literature by 1997. At the time, it was the most potent and selective dopamine D 3 receptor antagonist yet known.

In addition, the drug has been said to have been the first selective dopamine D 3 receptor antagonist. It was under development by Abbott Laboratories. The drug reached phase 2 clinical trials prior to the discontinuation of its development. ABT-925 is known to have been in active phase 2 trials between 2001 and 2007. It failed to show antipsychotic effectiveness in acute schizophrenia in a phase 2 trial published in 20111.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1358470072 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “ABT-925” revision 1358470072 · retrieved 2026-10-21 publication date (×1) · confidence 0.95 revision URL